This study aims to better understand people who have advanced or metastatic non-small cell lung cancer (NSCLC) with an EGFR mutation. NSCLC is an advanced stage cancer of the lung, occurring due to mutations (changes) in the EGFR gene. The study will assess the participant demographic background (that is age, gender etc.), the treatments they receive, how well those treatments work, and their health outcomes.
Histologically or cytologically confirmed diagnosis of advanced or metastatic unresectable non-small cell lung cancerNSCLC (TNM stages IIIB-IV), and a documented EGFR mutation, between 01 July 2018 and 31 March 2022
Diagnosed and treated at one of the participating study centers within the defined study period
Participants who received any systemic cancer treatment outside the participating treatment centers
Participants diagnosed with any other malignancy within the 5 years prior to or during the study period, with the exception of cutaneous basal cell carcinoma or squamous cell carcinoma
Participants enrolled in clinical trials during the study period.
Adult participants (aged greater than or equal to \[\>=\] 18 years) with a histologically or cytologically confirmed diagnosis of NSCLC, unresectable stage IIIB/C or IV at diagnosis, and a documented EGFR mutation.
Cohort
Retrospective
Not listed
Sociodemographic Characteristics: Age
Age in years of the participants will be reported.
Sociodemographic Characteristics: Sex
Sex (male, female) of the participants will be reported.
Sociodemographic Characteristics: Weight
Weight (in kilograms \[kg\]) of the participants will be reported.
Sociodemographic Characteristics: Smoking Status
Participants smoking status that is current or former smoker will be reported.
Frequency of EGFR Mutations
Frequency of EGFR mutations will be reported.
Number of Participants by Treatment Options
Participants with different treatment options such as targeted therapy, chemotherapy, immunotherapy, surgery, radiotherapy stratified by type of mutation will be reported.
Real-World Overall Survival (RW-OS)
RW-OS is defined as time elapsed between index date and date of death from any cause.
Real-World Progression-Free Survival (RW-PFS)
RW-PFS is defined as the time elapsed between the start of a new line of treatment to the date of documented disease progression or death from any cause, whichever occurs first.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
